Omeros (OMER) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Omeros Corporation  (NASDAQ: OMER)
 

Omeros Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Omeros Corporation inventory turnover ratio, the Omeros Corporation's ability to sell and replace its inventory in the second quarter 2026, sequentially increased to 2.97 in the second quarter 2026, OMER's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Omeros in Jun 30 2026 quarter, has decreased to 123 days, compare to 159 days, in the Mar 31 2026 quarter.

Within Healthcare sector Omeros Corporation achieved the highest inventory turnover ratio. While inventory turnover ranking remained unchanged in the Second Quarter 2026 compared to previous quarter at no. .

OMER Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Omeros Corporation Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OMER Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth - - - - -
Y / Y Cost of Sales Growth - - - - -
Inventory Turnover Ratio (TTM) 2.97 2.29 - - -
OMER's Total Ranking # # # # #
Average inventory processing period 123 159 - - -
Seq. Inventory Growth 360.11 % - - - -
Seq. Cost of Sales Growth 35.95 % - - - -




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Inventory Turnover Ratio Statistics
High Average Low
0 0 0
 



OMER Company Profile >> Back to OMER Efficiency Comparisons >> Compare OMER Inventory Turnover Ratio to its Competitors

Financial Statements
Omeros's Inventories $ 1 Millions Visit OMER's Balance sheet
Omeros's Cost of Revenues TTM $ 1 Millions Visit OMER's Income Statement
What are OMER's Sales? Visit OMER's Sales by Segment

Other Inventory Turnover Ratios
Omeros's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
OMER's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for OMER's Competitors
Inventory Turnover Ratio for OMER's Suppliers
Inventory Turnover Ratio for OMER's Customers

You may also want to know
OMER's Sales Growth Rates OMER's Pe Price to earnings ratio OMER's Receivables Turnover Ratio OMER's Stock Quote
OMER's Net Income Growth Rates OMER's Ps Price to Sales ratio OMER's Sales per Employee OMER's Asset Turnover Ratio
OMER's Net Margin OMER's Pb Price to Book ratio OMER's Financial Strength Ratios OMER's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Idexx Laboratories Inc  4.44 $ 1,714.440  Millions$ 386  Millions
Cryoport inc   4.40 $ 98.679  Millions$ 22  Millions
Envista Holdings Corporation  4.37 $ 1,278.500  Millions$ 293  Millions
Adc Therapeutics Sa  4.17 $ 5.806  Millions$ 1  Millions
Scilex Holding Company  4.08 $ 14.867  Millions$ 4  Millions
Medinotec Inc   4.08 $ 4.736  Millions$ 1  Millions
Alpha Teknova Inc   4.08 $ 28.288  Millions$ 7  Millions
3m Company  4.07 $ 15,258.000  Millions$ 3,754  Millions
Electromed Inc   4.02 $ 14.133  Millions$ 4  Millions
Novocure Limited  4.02 $ 166.921  Millions$ 41  Millions
Elite Pharmaceuticals Inc   3.95 $ 78.824  Millions$ 20  Millions
Lftd Partners Inc   3.89 $ 29.233  Millions$ 8  Millions
Pmgc Holdings Inc   3.87 $ 1.364  Millions$ 0  Millions
Sonoma Pharmaceuticals Inc   3.83 $ 13.392  Millions$ 3  Millions
Intelligent Bio Solutions Inc   3.80 $ 2.165  Millions$ 1  Millions
Iridex Corp  3.80 $ 32.517  Millions$ 9  Millions
Biocryst Pharmaceuticals Inc   3.69 $ 20.926  Millions$ 6  Millions
Teva Pharmaceutical Industries Limited  3.66 $ 8,232.000  Millions$ 2,250  Millions
Neuraxis Inc   3.55 $ 0.783  Millions$ 0  Millions
Beyond Air Inc   3.51 $ 6.447  Millions$ 2  Millions
Nexgel Inc   3.49 $ 7.577  Millions$ 2  Millions
Lifeward ltd   3.47 $ 13.976  Millions$ 4  Millions
Tandem Diabetes Care Inc   3.46 $ 456.703  Millions$ 132  Millions
Mirum Pharmaceuticals Inc   3.40 $ 85.221  Millions$ 25  Millions
Zai Lab Limited  3.39 $ 195.542  Millions$ 58  Millions
Bellevue Life Sciences Acquisition Corp  3.38 $ 1.215  Millions$ 0  Millions
Evolus Inc   3.37 $ 105.904  Millions$ 31  Millions
Gilead Sciences Inc   3.35 $ 6,217.000  Millions$ 1,857  Millions
10x Genomics Inc   3.29 $ 184.539  Millions$ 56  Millions
Biofrontera Inc   3.28 $ 6.622  Millions$ 2  Millions

Date modified: 2026-09-04T00:02:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.